Top

Inflammation Research

Published in:

01-11-2013 | Original Research Paper

The expression pattern of Nischarin after lipopolysaccharides (LPS)-induced neuroinflammation in rats brain cortex

Authors: Xiaohong Wu, Wei Xu, Gang Cui, Yaohua Yan, Xinmin Wu, Lei Li, Xiang Tan, Qiyun Wu, Xingxing Gu

Published in: Inflammation Research | Issue 11/2013

Abstract

Objective

To investigate whether Nischarin participated in neuronal apoptosis induced by neuroinflammation and via the phosphatidylinositol 3-kinase (PI3K) and PKB-dependent pathway.

Material

Use of male Sprague–Dawley rats, rat pheochromocytoma (PC12), and murine microglial cells (BV-2). Treatment lipopolysaccharides (LPS) were injected into the brain lateral ventricle of the rat. The BV-2 cells were treated by LPS. The PC12 cells were pretreated by or not pretreated by conditioned media and siRNA.

Methods

Western blotting was used for analyzing the expression level of Nischarin, pAKT, BAD and Bcl-2. Immunohistochemistry and immunofluorescence were used to perform the morphology and localization of Nischarin. The siRNA could down-regulate the protein level of endogenous Nischarin.

Results

The expression level of Nischarin was elevated after LPS injection; meanwhile, Nischarin was located in the neuron. Nischarin was involved in regulating the PI3K/PKB patway.

Conclusion

Nischarin might be involved in mediating the process of PI3K/PKB pathway-dependent neuronal apoptosis. After the silencing of Nischarin in cultured PC12 (pheochromocytoma) by siRNA, these results showed that it would induce a reduction of pAKT and Bcl-2 proteins expression; meanwhile, it induces an increase of BAD and active caspase-3.

Bonow RH, Aid S, Zhang Y, Becker KG, Bosetti F. The brain expression of genes involved in inflammatory response, the ribosome, and learning and memory is altered by centrally injected lipopolysaccharide in mice. Pharmacogenomics J. 2009;9:116–26.PubMedCrossRef

Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol. 1995;13:437–57.PubMedCrossRef

Yeh SH, Hung JJ, Gean PW, Chang WC. Hypoxia-inducible factor-1alpha protects cultured cortical neurons from lipopolysaccharide-induced cell death via regulation of NR1 expression. J Neurosci. 2008;28:14259–70.PubMedCrossRef

Burguillos MA, Hajji N, Englund E, Persson A, Cenci AM, Machado A, Cano J, Joseph B, Venero JL. Apoptosis-inducing factor mediates dopaminergic cell death in response to LPS-induced inflammatory stimulus: evidence in Parkinson’s disease patients. Neurobiol Dis. 2011;41:177–88.PubMedCrossRef

Hauss-Wegrzyniak B, Lukovic L, Bigaud M, Stoeckel ME. Brain inflammatory response induced by intracerebroventricular infusion of lipopolysaccharide: an immunohistochemical study. Brain Res. 1998;794:211–24.PubMedCrossRef

Zhang ZH, Yu Y, Wei SG, Felder RB. Centrally administered lipopolysaccharide elicits sympathetic excitation via NAD(P)H oxidase-dependent mitogen-activated protein kinase signaling. J Hypertens. 2010;28:806–16.PubMedCrossRef

Hu S, Peterson PK, Chao CC. Cytokine-mediated neuronal apoptosis. Neurochem Int. 1997;30:427–31.PubMedCrossRef

Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines in Parkinson’s disease. J Neural Transm Suppl. 2000;58:143–51.PubMed

Hyman BT, Yuan J. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat Rev Neurosci. 2012;13:395–406.PubMedCrossRef

10.

Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205–19.PubMedCrossRef

11.

Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315:856–9.PubMedCrossRef

12.

Alahari SK, Lee JW, Juliano RL. Nischarin, a novel protein that interacts with the integrin alpha5 subunit and inhibits cell migration. J Cell Biol. 2000;151:1141–54.PubMedCrossRef

13.

Yao M, Zhou XD, Zha XL, Shi DR, Fu J, He JY, Lu HF, Tang ZY. Expression of the integrin alpha5 subunit and its mediated cell adhesion in hepatocellular carcinoma. J Cancer Res Clin Oncol. 1997;123:435–40.PubMedCrossRef

14.

Lee JW, Juliano RL. alpha5beta1 integrin protects intestinal epithelial cells from apoptosis through a phosphatidylinositol 3-kinase and protein kinase B-dependent pathway. Mol Biol Cell. 2000;11:1973–87.PubMedCrossRef

15.

Alahari SK. Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK. Exp Cell Res. 2003;288:415–24.PubMedCrossRef

16.

Alahari SK, Reddig PJ, Juliano RL. The integrin-binding protein Nischarin regulates cell migration by inhibiting PAK. EMBO J. 2004;23:2777–88.PubMedCrossRef

17.

Ding Y, Milosavljevic T, Alahari SK. Nischarin inhibits LIM kinase to regulate cofilin phosphorylation and cell invasion. Mol Cell Biol. 2008;28:3742–56.PubMedCrossRef

18.

Dontenwill M, Piletz JE, Chen M, Baldwin J, Pascal G, Ronde P, Dupuy L, Greney H, Takeda K, Bousquetd P. IRAS is an anti-apoptotic protein. Ann N Y Acad Sci. 2003;1009:400–12.PubMedCrossRef

19.

Renton KW, Dibb S, Levatte TL. Lipopolysaccharide evokes the modulation of brain cytochrome P4501A in the rat. Brain Res. 1999;842:139–47.PubMedCrossRef

20.

del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687–9.PubMedCrossRef

21.

Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231–41.PubMedCrossRef

22.

Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996;87:619–28.PubMedCrossRef

23.

Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer’s disease pathology. Int J Dev Neurosci. 2006;24:157–65.PubMedCrossRef

24.

Bredesen DE. Neural apoptosis. Ann Neurol. 1995;38:839–51.PubMedCrossRef

25.

Naruse I, Keino H. Apoptosis in the developing CNS. Prog Neurobiol. 1995;47:135–55.PubMedCrossRef

26.

Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol. 1997;9:701–6.PubMedCrossRef

27.

Wick MJ, Dong LQ, Riojas RA, Ramos FJ, Liu F. Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein kinase-1. J Biol Chem. 2000;275:40400–6.PubMedCrossRef

28.

Berra E, Diaz-Meco MT, Moscat J. The activation of p38 and apoptosis by the inhibition of Erk is antagonized by the phosphoinositide 3-kinase/Akt pathway. J Biol Chem. 1998;273:10792–7.PubMedCrossRef

29.

Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a BAD influence. Cell. 1996;87:589–92.PubMedCrossRef

30.

Green D, Kroemer G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol. 1998;8:267–71.PubMedCrossRef

31.

Martin LJ. Neuronal cell death in nervous system development, disease, and injury (review). Int J Mol Med. 2001;7:455–78.PubMed

32.

Piletz JE, Ivanov TR, Sharp JD, Ernsberger P, Chang CH, Pickard RT, Gold G, Roth B, Zhu H, Jones JC, et al. Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization. DNA Cell Biol. 2000;19:319–29.PubMedCrossRef

33.

Dontenwill M, Pascal G, Piletz JE, Chen M, Baldwin J, Ronde P, Dupuy L, Urosevic D, Greney H, Takeda K, et al. IRAS, the human homologue of Nischarin, prolongs survival of transfected PC12 cells. Cell Death Differ. 2003;10:933–5.PubMedCrossRef

34.

Assoian RK. Anchorage-dependent cell cycle progression. J Cell Biol. 1997;136:1–4.PubMedCrossRef

35.

Zhang Z, Vuori K, Reed JC, Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA. 1995;92:6161–5.PubMedCrossRef

36.

Matter ML, Ruoslahti E. A signaling pathway from the alpha5beta1 and alpha(v)beta3 integrins that elevates bcl-2 transcription. J Biol Chem. 2001;276:27757–63.PubMedCrossRef

37.

Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905–27.PubMedCrossRef

38.

Fang L, Chen B, Liu S, Wang R, Hu S, Xia G, Tian Y, Cai X. Synergistic effect of a combination of nanoparticulate Fe3O4 and gambogic acid on phosphatidylinositol 3-kinase/Akt/Bad pathway of LOVO cells. Int J Nanomed. 2012;7:4109–18.

39.

Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, Greenberg ME. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell. 2000;6:41–51.PubMed

40.

Zheng J, Hu JD, Chen YY, Chen BY, Huang Y, Zheng ZH, Liu TB. Baicalin induces apoptosis in leukemia HL-60/ADR cells via possible down-regulation of the PI3K/Akt signaling pathway. Asian Pac J Cancer Prev. 2012;13:1119–24.PubMedCrossRef

41.

Chelyshev Iu A, Cherepnev GV, Saitkulov KI. Apoptosis in the nervous system. Ontogenez. 2001;32:118–29.PubMed

Title: The expression pattern of Nischarin after lipopolysaccharides (LPS)-induced neuroinflammation in rats brain cortex
Authors: Xiaohong Wu
Wei Xu
Gang Cui
Yaohua Yan
Xinmin Wu
Lei Li
Xiang Tan
Qiyun Wu
Xingxing Gu
Publication date: 01-11-2013
Publisher: Springer Basel
Published in: Inflammation Research / Issue 11/2013
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-013-0631-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Material

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2013

Therapeutic potential of biodegradable microparticles containing Punica granatum L. (pomegranate) in murine model of asthma

Silibinin inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling pathway in HMC-1 human mast cells

Myeloperoxidase deficiency in mice exacerbates lung inflammation induced by nonviable Candida albicans

Vimentin is a target of PKCβ phosphorylation in MCP-1-activated primary human monocytes

Suppression of Th1 cytokine production by a peptide derived from C4b

Inhibition of TRPM7 channels prevents proliferation and differentiation of human lung fibroblasts

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials